Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.
Baxter International Inc. reports news on its global medtech business, which supplies hospitals, physician offices and other care settings with connected solutions, medical devices and advanced injectable technologies. Company updates commonly cover results from continuing operations following the Kidney Care divestiture, portfolio activity in infusion therapies and platforms, surgical tables, smart stretchers, patient-support systems, monitoring tools, and hemostatic and sealing agents.
Baxter announcements also address product introductions such as the IV Verify Line Labeling System, conference showcases for Global Surgical Solutions, Advanced Surgery and Patient Support Systems, annual-meeting matters, executive finance leadership, and foundation partnerships tied to healthcare settings.
Baxter International Inc. (NYSE:BAX) will hold a conference call on February 9, 2023, at 7:30 a.m. Central Time to discuss its fourth-quarter 2022 financial results. Interested participants can pre-register through the provided link or access the call via Baxter’s website. The call will also be recorded for future reference. Baxter continues to be a leader in healthcare with a diverse portfolio including critical care, kidney care, and surgical products utilized globally. For more insights, visit www.baxter.com.
Baxter International Inc. (NYSE:BAX) has announced plans to spin off its Renal Care and Acute Therapies units into a publicly traded company within 12-18 months. This restructuring aims to simplify operations, enhance strategic focus, and improve long-term performance. Additionally, Baxter will explore strategic alternatives for its BioPharma Solutions business to optimize its capital structure. The proposed changes are designed to strengthen Baxter's market position and foster innovation, with sales for the renal unit in 2021 reaching $5 billion.
Summary not available.
The ExactaMix Pro Automated Compounder from Baxter International (NYSE:BAX), set for release in early 2023, enhances security and user experience while offering superior data reporting capabilities. It will be showcased at the ASHP Midyear Clinical Meeting from Dec. 4-8, 2022. This advanced system is certified to the FDA-recognized UL 2900-2-1 cybersecurity standard and provides features designed for increased efficiency and ease of use, including touchscreen responsiveness and 15 months of data storage. ExactaMix Pro signals a significant advancement in compounding technology.
Baxter International Inc. (NYSE:BAX) will participate in the 5th Annual Evercore ISI HealthCONx Conference on December 1, 2022, at 1:00 p.m. Eastern Time. Chief Financial Officer Jay Saccaro will present at the event. A live webcast will be available on www.baxter.com and can be replayed until May 30, 2023. With a legacy of 90 years, Baxter continues to innovate in areas like diagnostic and critical care solutions across over 100 countries, helping millions of patients and caregivers globally.
Baxter International Inc. (NYSE:BAX) has declared a quarterly cash dividend of $0.29 per share, payable on January 3, 2023. Shareholders of record by December 2, 2022 will receive this dividend. The annual dividend rate is set at $1.16 per share. Baxter continues to maintain its commitment to returning value to shareholders while focusing on innovations in healthcare.
Baxter International Inc. (NYSE:BAX) presented significant data at Kidney Week 2022 demonstrating the benefits of its remote patient management platform, Sharesource, and the Theranova dialyzer. A controlled study revealed that Sharesource improves outcomes for home peritoneal dialysis patients by reducing adverse events. Additionally, ex vivo studies indicated that Theranova effectively removes larger middle-molecule toxins while maintaining albumin stability during hemodialysis. These innovations aim to enhance patient care in response to the global kidney disease crisis.
Baxter International reported third-quarter 2022 revenue of $3.8 billion, a 17% increase on a reported basis. U.S. GAAP EPS was ($5.83), reflecting $3.1 billion in impairment charges from the Hillrom acquisition, attributed to rising interest rates and equity declines. Adjusted EPS was $0.82, a 20% decrease year-over-year. International sales grew 1%, while U.S. sales surged 40%. Despite challenges from supply constraints and competition, Baxter's product innovations continue to drive growth. The company anticipates 17%-18% sales growth for the full year.
Baxter International Inc. (NYSE:BAX) will host a conference call on October 27, 2022, at 7:30 a.m. Central Time to discuss its third-quarter financial results. Interested participants can pre-register for the call via the provided link. The call will also be webcasted through Baxter’s official website, where it will be accessible after the live session. Baxter provides critical healthcare products across multiple sectors, serving patients globally. For more information, visit www.baxter.com.
Baxter International Inc. (NYSE:BAX) has announced a commitment of $400,000 to create scholarships aimed at increasing diversity in healthcare professions. This includes the establishment of the Baxter Nursing Scholars Award at Tennessee State University's School of Nursing and the Baxter Healthcare Scholarship at Howard University College of Pharmacy. The initiative is part of Baxter's Activating Change Today initiative to advance racial justice and support underrepresented Black students in health and sciences.